

Review of: "Phyto-Therapeutic Potential and Pharmaceutical Impact of Shilajit (*Asphaltum punjabianam*): Current Research and Future Prospects"

Priyanka Kriplani

Potential competing interests: No potential competing interests to declare.

This article is already published with DOI:[10.32388/RIXY86](https://doi.org/10.32388/RIXY86).

There are no tables and figures, no clinical data, and no patent data. No new data or information is provided. There is no novelty.

There is not even a single clinical data/study discussed like application no. NCT02026414, NCT05573607, **NCT05887050**, **NCT02794454**, **NCT03558048**, etc.. Patented formulations are also not cited like US20180168198A1, US8110230B2, AU2021200959B2, US20210368842A1, US7250181B2, etc.

Any new formulations other than nanoformulations or any marketed formulations are not there, like Atlantis Nutrition Shilajit Supplement.

1. Dorado Shilajit Supplement 10,000mg
2. Nutricost Shilajit Capsules, and so on

In pharmacological activity data, the results mentioned must be in numerical terms to justify it. Like in antimicrobial activity, it is written, "Shilajit effectively inhibits E. Coli bacteria." What is the percentage of inhibition must be mentioned. Likewise, this must be followed in other activities.